In April, the variety of generic drugs of many pharmaceutical companies announced good news, and passed the consistency evaluation!

The normalization of centralized procurement is forcing pharmaceutical companies to accelerate the consistency evaluation work
.
Since April, a number of generic drug varieties from pharmaceutical companies have reported good news, and good news has passed the consistency evaluation, and many of them have passed the evaluation
.
Haisco: Arginine Glutamate Injection Review On April 2, Haisco announced that Liaoning Haisco Pharmaceutical, a wholly-owned subsidiary of the company, has recently received the "Approval for Supplementary Drug Application" issued by the State Drug Administration.
Notice", arginine glutamic acid injection successfully passed the consistency evaluation
.
Arginine Glutamate Injection was researched and developed by Morishita Pharmaceutical Co.
, Ltd.
at that time, and it was launched in Japan in November 1960
.
There are no imported preparations on the market in China, only Haisco products were approved for marketing in May 2015.
This review means that Haisco has won the first review
.
According to data from Minet.
com, in 2019, the terminal sales of arginine and glutamic acid injection in Chinese public medical institutions have exceeded 100 million yuan
.
The announcement also shows that arginine glutamic acid injection is a national medical insurance drug, which is mainly used for the adjuvant treatment of elevated blood ammonia caused by chronic liver disease
.
Arginine glutamate has a good effect on hyperammonemia, and plays an important role in improving liver function, central nervous system function and other physiological functions of the human body
.
In patients with hyperammonemia and liver injury, arginine glutamate injection treatment not only reduces blood ammonia levels and increases urea levels, but also improves the brain microenvironment
.
Asia-Pacific Pharmaceuticals: Over-evaluation of Omeprazole Sodium for Injection On April 2, Asia-Pacific Pharmaceuticals issued an announcement that the company recently received the Supplementary Drug Application for Omeprazole Sodium for Injection approved and issued by the State Drug Administration.
Approval Notice", Omeprazole Sodium for Injection passed the consistency evaluation of generic drugs
.
This product is a proton pump inhibitor, which is mainly used for: peptic ulcer bleeding, anastomotic ulcer bleeding; acute gastric mucosal damage complicated by stress state, acute gastric mucosal damage caused by non-steroidal anti-inflammatory drugs; prevention of severe diseases (such as cerebral hemorrhage, severe trauma, etc.
) stress state and upper gastrointestinal bleeding after gastric surgery, etc.
; as an alternative therapy for the following conditions when oral therapy is not suitable: duodenal ulcer, gastric ulcer, reflux esophagus inflammation and Zollinger-Ellison syndrome
.
It is reported that esomeprazole sodium for injection was developed by AstraZeneca and was approved to enter China in 2007.
In 2019, AstraZeneca obtained the qualification for localized production
.
According to data from Minet.
com, the terminal sales of omeprazole sodium for injection in domestic urban public hospitals in 2021 will be about 3.
951 billion yuan
.
At present, the main domestic manufacturers of the drug include Chia Tai Tianqing, Haisco, Osaikang,
etc.
Asia Pacific Pharmaceuticals stated that the over-evaluation of the company's omeprazole sodium for injection is conducive to enhancing the market competitiveness of the drug, and at the same time accumulating experience for the company's subsequent generic drug consistency evaluation for other products
.
Since drug research and development, production and sales are easily affected by national policies, market environment and other factors, there is great uncertainty.
Investors are advised to make decisions with caution and pay attention to investment risks
.
Lukang Pharmaceutical: Review of Ceftriaxone for Injection On April 1, Lukang Pharmaceutical released the good news that ceftriaxone sodium for injection passed the consistency evaluation.
g) The application will be accepted in February 2021, and the National Bureau has indicated that it has approved the supplement
.
Ceftriaxone sodium for injection is suitable for infections caused by pathogenic bacteria sensitive to this product
.
At present, ceftriaxone sodium is a 2020 version of the National Medical Insurance Category A and a 2018 version of the National Essential Drug List
.
According to the data of Minenet, the overall market size of ceftriaxone injection in China's public medical institutions in 2020 is about 3.
15 billion yuan, and the market prospect is broad
.
The company said that the approval of the consistency evaluation of ceftriaxone sodium for injection will further enhance the company's market competitiveness and provide new impetus for the company's high-quality development
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.